Dermatology - Page 9
The MD Magazine Dermatology - Page 9 specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


What Is the Risk of Skin Cancer in Patients with Atopic Dermatitis?
Are people with atopic dermatitis at a higher or lower risk of developing skin cancer? Researchers found conflicting evidence.
In the past 15 years, no new topical AD treatments have been approved. Crisaborole, however, could be an efficient, safe, non-steoidal treatment option, according to the results of two recent phase III studies.
Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
The process for treatment of plaque psoriasis can be a very involved process depending on their history with the condition and other issues they may have as well. This can include psoriatic arthritis.
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
An experimental inpatient program worked for atopic dermatitis that had not been resolved despite treatment.
French investigators did a retrospective study of atopic dermatitis treatment and found immunosuppressive agents were well tolerated and worked.
The antifungal, sertaconazole (Ertaczo, Valeant, others), was no better than the topical vehicle placebo in a well controlled, multicenter trial to treat unremitting pruritus in atopic dermatitis (AD).
For patients diagnosed with plaque psoriasis there can be other health issues to consider as well. This can include heart attack, stroke, and obesity as well as obesity and others.

Most Popular in Dermatology - Page 9

Recent Published Journal


$vacMongoViewPlus$ $vAR$